Roche Diagnostics and BioPorto expand collaboration
February 20, 2024 02:28 ET
|
BioPorto A/S
20 February 20, 2024Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the...
BioPorto A/S to host investor meetings on 22 February 2024
February 19, 2024 01:41 ET
|
BioPorto A/S
19 February 2024News Release BioPorto A/S to host investor meetings on 22 February 2024 COPENHAGEN, DENMARK and BOSTON, Mass., 19 February 2024, BioPorto A/S (BioPorto or Company), an...
BioPorto implements changes to the Executive Management.
January 09, 2024 13:42 ET
|
BioPorto A/S
January 9, 2024 Announcement no. 01 BioPorto implements changes to the Executive Management. COPENHAGEN, DENMARK and BOSTON, MA, January 9, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the...
Managers’ transactions
December 09, 2023 12:12 ET
|
BioPorto A/S
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company)...
FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)
December 08, 2023 11:02 ET
|
BioPorto A/S
8 December 2023 News Release FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI) One in four children can develop life-threatening kidney...
BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år
December 08, 2023 02:13 ET
|
BioPorto A/S
8. december 2023 Pressemeddelelse BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år BioPorto A/S...
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
December 07, 2023 16:22 ET
|
BioPorto A/S
December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United StatesFirst Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years ...
Resignation of Director
December 04, 2023 14:00 ET
|
BioPorto A/S
December 4, 2023Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR)...
BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference
November 01, 2023 12:40 ET
|
BioPorto A/S
November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023,...
BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023
November 01, 2023 03:31 ET
|
BioPorto A/S
November 1, 2023Announcement no. 18 BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 COPENHAGEN, Denmark and...